Advertisement
Screener

MAZE THERAPEUTICS, INC. (MAZE) Graph

MAZE Revenue Flow

Filed revenue amounts for 2026-01-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue (m); Research and development $34.94M; Operating expenses $48.03M; Income tax (m).
  • 2026-03-31: Revenue $20.00M; Research and development $34.15M; Operating expenses $46.55M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $27.57M*; Operating expenses $38.06M*; Income tax $0.00*.
  • 2025-09-30: Revenue (m); Research and development $25.19M; Operating expenses $32.97M; Income tax $0.00.

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

MAZE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.US$20.00MRevenue$20.00MOperating expenses$94.59MOperating income-$74.59MOther income, net$5.65MResearch & development$69.09MNet income-$68.94M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$34.94M$48.03M(m)-$44.73M
2026-03-31$20.00M$34.15M$46.55M(m)-$24.21M
2025-12-31(m)$27.57M*$38.06M*$0.00*-$34.57M*
2025-09-30(m)$25.19M$32.97M$0.00-$30.09M
2025-06-30$0.00$28.11M$36.47M$0.00-$33.68M
2025-03-31(m)$27.58M$35.40M(m)-$32.79M
2024-09-30$2.50M$19.86M$26.73M-$279.00K-$24.75M
2024-06-30$165.00M$19.55M$25.45M$1.73M$139.06M
2024-03-31(m)$21.88M$28.01M(m)-$32.49M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$20.00M$69.09M$94.59M(m)-$68.94M
2025-06-30$0.00$55.69M$71.88M$0.00-$66.47M
2024-06-30$165.00M$41.42M$53.46M$1.73M$106.56M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$80.88M$104.84M$0.00-$96.55M
2024-09-30$167.50M$61.28M$80.19M$1.45M$81.81M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$108.45M$142.90M$0.00-$131.12M
2024-12-31$167.50M$83.50M$109.91M$1.17M$52.23M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Immunocore Holdings plc (IMCR)$1.613B-90.43
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
NOVAVAX INC (NVAX)United States$1.748B-6.26
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81